Mazin Magzoub is a biophysicist specializing in the development of novel methods
for the delivery of antitumor agents and therapeutics for amyloid diseases (e.g.
Alzheimer’s and prion diseases). Prior to joining NYUAD, Dr. Magzoub was a
postdoctoral scholar at the University of California, San Francisco, where he
developed novel biophysical methods for measurement of macromolecule diffusion
deep in tissues such as tumors and brain. Subsequently, as an Associate Research
Scientist in Andrew Miranker’s laboratory at Yale University, he worked on
elucidating the molecular mechanisms underlying type 2 diabetes.
Dr. Magzoub received his Ph.D. in biophysics from Stockholm University in 2004,
where he studied the biophysical properties of cell-penetrating peptides, a class of
peptides with the ability to mediate the cellular import of therapeutic compounds with
high efficiency and low toxicity.